Bone Biologics Corp 美股招股说明书（2026年3月13日版）

PROSPECTUS SUPPLEMENT(to prospectus dated September 2, 2025) BONE BIOLOGICS CORPORATION Up to $1,064,000 of Shares of Common Stock We have entered into an At The Market Offering Agreement dated September 27, 2024 (the “Sales Agreement”) with H.C. Wainwright& Co., LLC (“Wainwright” or the “Sales Agent”), relating to shares of our common stock, $0.001 par value per share (“commonstock”), offered by this prospectus supplement and the accompanying prospectus. In accordance with the terms of the SalesAgreement, from time to time we may offer and sell shares of our common stock through Wainwright acting as sales agent orprincipal. Pursuant to this prospectus supplement and the accompanying prospectus, from time to time we may offer and sell shares ofour common stock having an aggregate offering price of up to $1,064,000. As of March 13, 2026, we have issued and sold an Our common stock is traded on the Nasdaq Capital Market of the Nasdaq Stock Market LLC (“Nasdaq”) under the symbol “BBLG”.On March 10, 2026, the last reported sale price of our common stock on Nasdaq was $1.28 per share. Sales of our common stock, if any, under this prospectus supplement and the accompanying prospectus may be made in sales deemedto be an “at the market offering” as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended (the“Securities Act”), including sales made directly on or through the Nasdaq Capital Market, the existing trading market for our commonstock, or any other existing trading market in the United States for our common stock, sales made to or through a market maker otherthan on an exchange or otherwise, directly to Wainwright as principal, in negotiated transactions at market prices prevailing at the timeof sale or at prices related to such prevailing market prices, and/or in any other method permitted by law. Subject to terms of the Sales The Sales Agent will be entitled to compensation under the terms of the Sales Agreement at a commission rate of up to 3.0% of thegross sales price per share sold. In connection with the sale of our shares of common stock on our behalf, the Sales Agent will bedeemed to be an “underwriter” within the meaning of the Securities Act and the compensation of the Sales Agent will be deemed to beunderwriting commissions or discounts. We have also agreed to provide indemnification and contribution to the Sales Agent withagainst certain liabilities, including liabilities under the Securities Act. See the section titled “Plan of Distribution” on page S-10 of this We are subject to General Instruction I.B.6 of Form S-3, which limits the amounts that we may sell under the registration statement ofwhich this prospectus supplement is a part. The aggregate market value of our common stock held by non-affiliates pursuant toGeneral Instruction I.B.6 of Form S-3 is $3,194,365, which was calculated based on 1,794,587 shares of our common stockoutstanding held by non-affiliates as of March 10, 2026 and a price of $1.78 per share, the closing price of our common stock onJanuary 16, 2026. During the 12 calendar months prior to and including the date of this prospectus, we have not offered and sold anyof our securities pursuant to General Instruction I.B.6 of Form S-3. After giving effect to these limitations and the current public floatof our common stock, and after giving effect to the terms of the Sales Agreement, we currently may offer and sell shares of our Investing in our securities involves a high degree of risk. See the section entitled “Risk Factors”beginning on page S-7, theaccompanying prospectus and the documents incorporated by reference herein and therein for a discussion of the risks that Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of thesesecurities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense. H.C. Wainwright & Co. TABLE OF CONTENTS PROSPECTUS SUPPLEMENT PROSPECTUS ABOUT THIS PROSPECTUS SUPPLEMENT This document is in two parts. The first part is this prospectus supplement, which describes the specific terms of this offering ofsecurities and updates the information contained in the accompanying prospectus and the documents incorporated by reference hereinand therein. The second part is the accompanying prospectus, which provides more general information, some of which does not applyto this offering. To the extent the information contained in this prospectus supplement differs or varies from the information containedin the accompanying prospectus or documents previously filed with the U.S. Securities and Exchange Commission (the “SEC”) that This prospectus supplement is part of a shelf registration statement on Form S-3 (File No. 333-288290), as amended, that was initiallyfiled with the SEC on June 24, 2025, and became effective on September 2, 2025. Under the shelf registration process, we may fromtime to time of